First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
These courses are for pre-selected candidates who have completed their MBBS with an additional 2 years of surgical experience training
Appoints Dr Rafiq Hasan as CEO
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
CDSCO to fast-track trials and approval for COVID19 vaccine
Subscribe To Our Newsletter & Stay Updated
